| Authors: |
Mia MM; Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School Singapore, Singapore, Singapore., Ghani SABA; Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School Singapore, Singapore, Singapore., Cibi DM; Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School Singapore, Singapore, Singapore., Bogireddi H; Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School Singapore, Singapore, Singapore., Nilanthi U; Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School Singapore, Singapore, Singapore., Selvan A; Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School Singapore, Singapore, Singapore., Wong WSF; Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore.; Singapore-HUJ Alliance for Research and Enterprise, Molecular Mechanisms of Inflammatory Disease Program, National University of Singapore, Singapore, Singapore.; Drug Discovery and Optimization Platform, Yong Loo Lin School of Medicine, Singapore, Singapore., Singh MK; Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School Singapore, Singapore, Singapore manvendra.singh@duke-nus.edu.sg.; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore. |
